Michael Wagner

Michael Wagner serves as Senior Vice President, Chemistry and Drug Discovery at Dewpoint Therapeutics. Before joining Dewpoint, Michael helped to build several early-stage biotech companies in the field of drug discovery, biomolecular imaging and drug delivery.

Previously, he was leading the Synthetic Medicinal Modalities Department at Sanofi, taking care of the Frankfurt small molecule portfolio, peptide drug discovery, synthetic proteins and conjugates, but also new delivery technologies for sustained, oral and smart delivery of biomolecules.

During his 20-year career in the pharmaceutical industry, in positions with increasing responsibility, Michael has built a successful track record of building and leading functional groups to drive drug discovery and delivering high quality candidates for clinical development comprising different therapeutic modalities in multiple therapeutic areas, including cardiovascular disease, metabolic disease, pain, immunology and rare disease. His direct scientific contributions have resulted in more than 15 clinical development candidates and more than 80 patents or peer-reviewed publications.

Michael has served on numerous scientific advisory boards and is active in various professional societies for the advancement of chemical sciences and peptide sciences. Michael holds a PhD in organic and bioorganic chemistry from the University of Mainz, Germany.